Gemcabene

Drug Profile

Gemcabene

Alternative Names: CI 1027; PD 072953

Latest Information Update: 02 Dec 2016

Price : $50

At a glance

  • Originator Pfizer
  • Developer Gemphire Therapeutics; Pfizer
  • Class Antihyperlipidaemics; Caproates; Small molecules
  • Mechanism of Action Acetyl-CoA carboxylase inhibitors; Lipoprotein A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypercholesterolaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypercholesterolaemia; Hyperlipoproteinaemias; Hypertriglyceridaemia

Most Recent Events

  • 28 Nov 2016 Phase-II clinical trials in Hypertriglyceridaemia in USA (PO) (NCT02944383)
  • 01 Nov 2016 Gemphire Therapeutics initiates the phase II ROYAL-1 trial for Hypercholesterolaemia in USA (NCT02634151)
  • 31 Oct 2016 Gemphire Therapeutics has patent protection for Gemcabene in Mexico before October 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top